Boehringer Ingelheim International

• Ferulic acid eicosyl ester enhances cognitive flexibility and modulates arousal-related neural circuits in mice

  Consulting or advice, Board or leadership role, 30 Aug 2026

• Associations of Hearing Loss Defined by Updated World Health Organization Criteria With Socioeconomic Status and Health Check-Up-Related Factors: A Population-Based Cross-Sectional Study in Japan

  Fees or honoraria, 1 Aug 2026

• Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes

  Employment, 1 Nov 2024

Sources: pubmed.ncbi.nlm.nih.gov

• Dementia Progression with GLP-1 Receptor Agonists in People with Type 2 Diabetes and Mild Cognitive Impairment: Retrospective Cohort Study

  ADA Scientific Sessions 2026 abstract, 8 Jun 2026

• Orforglipron vs. Dapagliflozin in Type 2 Diabetes Inadequately Controlled with Metformin

  ADA Scientific Sessions 2026 abstract, 7 Jun 2026

• Greater Combined A1C Reductions and Weight Loss with 25 mg and 50 mg vs. 14 mg Oral Semaglutide in Adults with T2D: Evidence from PIONEER PLUS

  ADA Scientific Sessions 2026 abstract, 6 Jun 2026

• Waist-to-Height Ratio Outperforms BMI in Identifying Hepatic Steatosis and Fibrosis in U.S. Adults

  ADA Scientific Sessions 2026 abstract, 6 Jun 2026

• Trends in Utilization of Glucose Lowering Medications among Patients with Type 1 Diabetes in the United States

  ADA Scientific Sessions 2026 abstract, 6 Jun 2026

• Differences in Outcomes of a University-Based Diabetes Prevention Program by Participant-Level Characteristics

  ADA Scientific Sessions 2026 abstract, 6 Jun 2026

• Addition of GLP-1 Analogs to DM1 Patients Using Automatic Insulin Delivery (AID) (MiniMed 780G): A Retrospective Real-Life Study

  ADA Scientific Sessions 2026 abstract, 6 Jun 2026

• Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Type 1 Diabetes: A Target Trial Emulation Study

  ADA Scientific Sessions 2026 abstract, 6 Jun 2026

• Vascular Age Gap Based on Carotid Intima-Media Thickness as a Marker of Early Vascular Aging in Adults with Type 1 Diabetes and Its Association with Diabetic Complications

  ADA Scientific Sessions 2026 abstract, 6 Jun 2026

• Body Mass Index and Blood Pressure Changes During and After Antiobesity Medication Use

  ADA Scientific Sessions 2026 abstract, 5 Jun 2026

• Cardiometabolic Risk Trajectories On and After Antiobesity Medication Use

  ADA Scientific Sessions 2026 abstract, 5 Jun 2026

• Machine-Learning Algorithm to Identify Carriers of the G6PD rs1050828 Variant in African American Men

  ADA Scientific Sessions 2026 abstract, 5 Jun 2026

• Obesity Prevalence in the Patient Neighborhood and Outcomes of Antiobesity Medication Mediated by Treatment Continuation: Structured Equation Modeling Approach

  ADA Scientific Sessions 2026 abstract, 5 Jun 2026

• Cognitive Screening in Older Adults with Type 1 Diabetes: Which Tools Best Detect Potential Cognitive Decline?

  ADA Scientific Sessions 2026 abstract, 5 Jun 2026

• Early Detection of Malnutrition in Elderly Patients with DM: The Key Importance of Functional Examination

  ADA Scientific Sessions 2026 abstract, 5 Jun 2026

• Exercise Snacks Can Alter Physical Activity Patterns and Increase Vigorous Activity in People Living with Type 2 Diabetes: Analyses of Three Randomized Trials

  ADA Scientific Sessions 2026 abstract, 5 Jun 2026

• Does the Inclusion of Lipoprotein(a) Levels Alter Cardiovascular Risk Assessment in Adults with Type 1 Diabetes Assessed Using the Steno T1 Risk Engine? Secondary Data Analysis from the InLipoDiab1 Cohort

  ADA Scientific Sessions 2026 abstract, 5 Jun 2026